# EDGAR Filing Document

**Accession Number:** 0001505497
**File Stem:** 0001493152-25-024082
**Filing Date:** 2025-11
**Character Count:** 20212
**Document Hash:** a389987fe34bc061874e45318247d99c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-024082.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001493152-25-024082

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**EFFECTIVENESS DATE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioRestorative Therapies, Inc.
- **CENTRAL INDEX KEY:** 0001505497
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 301341024
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291624
- **FILM NUMBER:** 251495472

**BUSINESS ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747
- **BUSINESS PHONE:** (631) 760-8100

**MAIL ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stem Cell Assurance, Inc.
- **DATE OF NAME CHANGE:** 20101110

As filed with the Securities and Exchange Commission on November 18, 2025

Registration No. 333-

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**BIORESTORATIVE THERAPIES, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Nevada**

(State or Other Jurisdiction of Incorporation or Organization)

**30-1341024**

(I.R.S. Employer Identification No.)

**40 Marcus Drive, Suite One, Melville, New York 11747**

(Address of Principal Executive Offices) (Zip Code)

**BioRestorative Therapies, Inc. 2021 Stock Incentive Plan**

(Full Title of the Plan)

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br> **Lance Alstodt**<br> **Chief Executive Officer**<br> **BioRestorative Therapies, Inc.**<br> **40 Marcus Drive, Suite One**<br> **Melville, New York 11747**<br> (Name and Address of Agent for Service) | &nbsp;&nbsp;***Copy to:***<br> **Fred S. Skolnik, Esq.**<br> **Certilman Balin Adler & Hyman, LLP**<br> **90 Merrick Avenue**<br> **East Meadow, New York 11554**<br> **(516) 296-7048** |

---

**(631) 760-8100**

(Telephone Number, Including Area Code, of Agent for Service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

**EXPLANATORY NOTE**

This Registration Statement covers an additional 3,000,000 shares of common stock, $0.0001 par value per share ("Common Stock"), of BioRestorative Therapies, Inc., a Nevada corporation (the "Registrant"), available for issuance under the Registrant's 2021 Stock Incentive Plan (the "2021 Plan"). This Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the 2021 Plan by reason of any stock dividend, stock split, recapitalization or similar transaction that results in an increase in the number of outstanding shares of Common Stock of the Registrant.

**STATEMENT PURSUANT TO GENERAL INSTRUCTION E TO FORM S-8**

Pursuant to General Instruction E to Form S-8 under the Securities Act, this Registration Statement is filed by the Registrant to register an additional 3,000,000 shares of Common Stock as to which options or awards may be granted under the 2021 Plan.

On April 30, 2021, the Registrant filed a Registration Statement on Form S-8 (File Number 333-255681) (the "First Registration Statement") in order to register 1,175,000 shares of Common Stock issuable under the 2021 Plan (giving retroactive effect to the 1-for-4,000 reverse split of the Registrant's shares of common stock effected as of October 27, 2021). On March 28, 2023, the Registrant filed a Registration Statement on Form S-8 (File Number 333-270909) (the "Second Registration Statement") in order to register 1,325,000 shares of Common Stock issuable under the 2021 Plan. On November 15, 2023, the Registrant filed a Registration Statement on Form S-8 (File Number 333-275571) (the "Third Registration Statement") in order to register 1,350,000 shares of Common Stock issuable under the 2021 Plan. On November 13, 2024, the Registrant filed a Registration Statement on Form S-8 (File Number 333-283197) (the "Fourth Registration Statement") in order to register 3,000,000 shares of Common Stock issuable under the 2021 Plan.

Pursuant to General Instruction E to Form S-8, the contents of the First Registration Statement, the Second Registration Statement, the Third Registration Statement and the Fourth Registration Statement, including the documents incorporated by reference therein, are hereby incorporated by reference into this Registration Statement, except to the extent supplemented, amended or superseded by the information set forth herein.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. <u>Incorporation of Documents by Reference</u>.**

Incorporated herein by reference are the following documents filed by the Registrant with the Securities and Exchange Commission (the "Commission") under the Securities Exchange Act of 1934, as amended (the "Exchange Act") (to the extent filed and not furnished):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/form10-k.htm) for the year ended December 31, 2024, filed with the Commission on March 28, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Quarterly
 Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/1505497/000164117225010299/form10-q.htm) for the period ended March 31, 2025, filed with the Commission on May 14, 2025.

(c) Quarterly
 Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/1505497/000164117225023211/form10-q.htm) for the period ended June 30, 2025, filed with the Commission on August 12, 2025.

(d) Quarterly
 Report on [Form 10-Q](https://www.sec.gov/Archives/edgar/data/1505497/000149315225021993/form10-q.htm) for the period ended September 30, 2025, filed with the Commission on November 12, 2025.

(e) Current Report on [Form 8-K](https://www.sec.gov/Archives/edgar/data/1505497/000102177125000074/brt42125.htm) filed with the Commission on April 21, 2025.

(f) Current Report on [Form 8-K](https://www.sec.gov/Archives/edgar/data/1505497/000102177125000131/brt91825.htm) filed with the Commission on September 25, 2025.

(g) Current Report on [Form 8-K](https://www.sec.gov/Archives/edgar/data/1505497/000149315225017446/form8-k.htm) filed with the Commission on October 8, 2025.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated herein by reference and to be a part hereof from their respective dates of filing.

**Item 5. <u>Interests of Named Experts and Counsel</u>.**

Certain legal matters in connection with the offering of the securities registered hereunder are being passed upon for the Registrant by Certilman Balin Adler & Hyman, LLP, 90 Merrick Avenue, East Meadow, New York 11554, a stockholder of the Registrant.

**Item 6. <u>Indemnification of Directors and Officers</u>.**

The Registrant is governed by Chapter 78 of the Nevada Revised Statutes (the "NRS"). Section 78.7502(1) of the NRS provides that a corporation may, and the Registrant's Amended and Restated Articles of Incorporation ("Articles") and By-Laws provide that the Registrant shall, indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (an "Action"), by reason of the fact that he is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation in such capacity in another corporation, partnership, joint venture, trust or other enterprise (the "Indemnified Party"), against expenses (including attorney's fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful; provided, however, no indemnification shall be made in respect of any Actions by or in the right of the corporation if the Indemnified Party shall have been adjudged by a court of competent jurisdiction, after exhaustion of any appeals, to be liable to the corporation, unless and only to the extent that the court shall determine that, despite the adjudication of liability but in view of all circumstances, such person is fairly and reasonably entitled to indemnity.

Under the NRS, the directors have a fiduciary duty to the Registrant that is not eliminated by this provision of the Articles and, in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available. In addition, each director will continue to be subject to liability under the NRS for breach of the director's duty of loyalty to the Registrant for acts or omissions which are found by a court of competent jurisdiction to not be in good faith or involve intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are prohibited by the NRS. This provision also does not affect the directors' responsibilities under any other laws, such as the federal securities laws or state or federal environmental laws.

Furthermore, Section 78.7502(3) of the NRS provides that determination of an Indemnified Party's eligibility for indemnification by the Registrant shall be made on a case-by-case basis by: (i) the stockholders; (ii) the board of directors by a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding; or (iii) independent legal counsel's written opinion if: (1) a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders; or (2) a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained.

Lastly, Section 78.752(1) of the NRS empowers a corporation to purchase and maintain insurance or make other financial arrangements with respect to liability arising out of the actions or omissions of directors, officers, employees or agents in their capacity or status as such, whether or not the corporation has the authority to indemnify him against such liability.

The Articles provide that, to the fullest extent permitted by the NRS, no director or officer shall be personally liable to the Registrant or to its stockholders for monetary damages for breach of fiduciary duty as a director or an officer, except to the extent that such exemption from liability or limitation thereof is not permitted under the NRS currently in effect or as the same may be amended. If the NRS is amended to further eliminate or limit or authorize corporate action to further eliminate or limit the liability of directors or officers, the liability of directors and officers of the Registrant shall be eliminated or limited to the fullest extent permitted by the NRS, as so amended from time to time. No repeal or modification of this provision of the Articles will apply to or have any effect on the liability or alleged liability of any director or officer of the Registrant for or with respect to any acts or omissions of such directors or officers occurring prior to such repeal or modification.

The Registrant's Bylaws provide that the Registrant will indemnify and hold harmless any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, in such manner, under such circumstances and to the fullest extent permitted by the Articles and the NRS.

**Item 8. <u>Exhibits</u>.**

---

| | |
|:---|:---|
| 5.0 | [Opinion of Certilman Balin Adler & Hyman, LLP as to the legality of the additional shares of Common Stock being registered by this Registration Statement](ex5.htm) |
| 23.1 | [Consent of Marcum LLP](ex23-1.htm) |
| 23.2 | [Consent of Certilman Balin Adler & Hyman, LLP (included in the opinion filed as Exhibit 5 hereto)](ex5.htm) |
| 107.0 | [Filing Fee Table](ex107.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Suffolk, State of New York, on the 18<sup>th</sup> day of November, 2025.

---

| | |
|:---|:---|
| **BIORESTORATIVE THERAPIES, INC.** | **BIORESTORATIVE THERAPIES, INC.** |
| By: | */s/ Lance Alstodt* |
|  | Lance Alstodt |
|  | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Capacity** | **Date** |
| */s/ Lance Alstodt* | Chief Executive Officer, President, and Chairman of the Board | November 18, 2025 |
| Lance Alstodt | (Principal Executive Officer) |  |
| */s/ Francisco Silva* | Vice President, Research and Development, Secretary and Director | November 18, 2025 |
| Francisco Silva |  |  |
| */s/ Robert E. Kristal* | Chief Financial Officer | November 18, 2025 |
| Robert E. Kristal | (Principal Financial Officer and Principal Accounting Officer) |  |
| */s/ Nickolay Kukekov* | Director | November 18, 2025 |
| Nickolay Kukekov |  |  |
| */s/ Patrick F. Williams* | Director | November 18, 2025 |
| Patrick F. Williams |  |  |
| */s/ David Rosa* | Director | November 18, 2025 |
| David Rosa |  |  |

---

## Ex-5

**Exhibit 5**

**OPINION OF CERTILMAN BALIN ADLER & HYMAN, LLP**

November 18, 2025

BioRestorative Therapies, Inc.

40 Marcus Drive

Melville, New York 11747

Re: Registration of 3,000,000 shares of Common Stock,

par value $0.0001 per share, under the

<u>Securities Act of 1933, as amended</u> 

Gentlemen:

In our capacity as counsel to BioRestorative Therapies, Inc., a Nevada corporation (the "Company"), we have been asked to render this opinion in connection with a Registration Statement on Form S-8 being filed contemporaneously herewith by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Registration Statement"), covering the issuance of up to an aggregate of 3,000,000 shares of common stock, par value $0.0001 per share, of the Company (the "Common Shares") under the Company's 2021 Stock Incentive Plan (the "2021 Plan").

In that connection, we have examined the Amended and Restated Articles of Incorporation and the By-Laws of the Company, as amended to date, the Registration Statement and the 2021 Plan and are familiar with corporate proceedings of the Company relating to the adoption of the 2021 Plan. We have also examined such other instruments and documents as we deemed relevant under the circumstances.

For purposes of the opinions expressed below, we have assumed (i) the authenticity of all documents submitted to us as original, (ii) the conformity to the originals of all documents submitted as certified, photostatic or facsimile copies and the authenticity of the originals, (iii) the legal capacity of natural persons, (iv) the due authorization, execution and delivery of all documents by all parties and the validity and binding effect thereof and (v) the conformity to the proceedings of the Board of Directors of all minutes of such proceedings. We have also assumed that the corporate records furnished to us by the Company include all corporate proceedings taken by the Company to date.

Based upon and subject to the foregoing, we are of the opinion that the Common Shares have been duly and validly authorized and, when issued pursuant to the terms of the 2021 Plan, will be duly and validly issued, fully paid and nonassessable.

We hereby consent to the use of our opinion as herein set forth as an exhibit to the Registration Statement.

This opinion is as of the date hereof, and we do not undertake, and hereby disclaim, any obligation to advise you of any changes in any of the matters set forth herein.

We are rendering this opinion only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

This opinion is for your exclusive use only and is to be utilized and relied upon only in connection with the matters expressly set forth herein.

---

| |
|:---|
| Very truly yours, |
| **CERTILMAN BALIN ADLER & HYMAN, LLP** |

---

## Exhibit 23.1

**Exhibit 23.1**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 27, 2025 with respect to the consolidated financial statements of BioRestorative Therapies, Inc. (the "Company") for the years ended December 31, 2024 and 2023 included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2024.

/s/ Marcum LLP

Marlton, New Jersey

November 18, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Table**

**FORM S-8**

(Form Type)

**BIORESTORATIVE THERAPIES, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

**** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Security Type** | <br>**Security Class Title** | <br>**Fee Calculation Rule** | **Maximum Aggregate Offering Price** | <br>**Fee Rate** | **Amount of**<br> **Registration**<br> **Fee** |
| Equity | Common Stock, par value $0.0001 per share | 457(h)(1)3000000<sup>(1)</sup>$1.30<sup>(2)</sup> | $3900000 | 0.00013810 | $538.59 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | $3900000 |  | $538.59 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |
| Net Fee Due | Net Fee Due | Net Fee Due |  |  | $538.59 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) under
 the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional
 shares of the Registrant's common stock that become issuable as a result of any stock dividend, stock split, recapitalization,
 or other similar transaction effected without the receipt of consideration that results in an increase in the number of outstanding
 shares of the Registrant's common stock.

(2) Calculated solely for purposes
 of the registration fee for this offering and in accordance with paragraph (h)(1) of Rule 457 of the Securities Act, on the basis of
 the average of the high and low prices of the Registrant's shares of common stock as quoted on the Nasdaq Capital Market on November
 14, 2025.

N/A